Zheng Yalin, Nong Lin, Liang Li, Wang Wei, Li Ting
Department of Pathology, Peking University First Hospital, 8 Xishiku Street, Xicheng District, Beijing, 100034, China.
Diagn Pathol. 2018 Feb 20;13(1):14. doi: 10.1186/s13000-018-0691-2.
Mast cell leukemia (MCL) is a very rare form of systemic mastocytosis (SM) and accounts for less than 0.5% of all mastocytosis. The diagnosis of MCL requires the presence of SM criteria, accompanied by leukemic infiltrating of atypical mast cells (MCs) in bone marrow (BM), peripheral blood as well as extracutaneous organs. MCL is a fatal disease that almost always behaves aggressively, and the median survival time is only about six months. Herein, we present a rare case of de novo MCL without CD25 expression and KIT mutations.
A previously healthy 13-year-old boy was referred to our hospital due to incidental discovery of an enlarged right tonsil. Diffuse infiltration of medium-sized hematopoietic blasts was found in his right tonsil, BM and multiple lymph nodes. The neoplastic cell population was subsequently revealed to exhibit differentiation towards the mast cell lineage by expressing CD117 and tryptase, but the cell population lacked expression of CD25/CD2 and the activating mutation of the KIT gene. An abnormal karyotype was identified, but no leukemia-associated fusion genes were found. Involvement of peripheral blood, bone and lung was subsequently demonstrated. The most important differential diagnosis included tryptase-positive (T+) acute myeloid leukemia, myelomastocytic leukemia and basophilic leukemia. The morphological characteristics and infiltrating patterns of the abnormal MCs supported the final diagnosis of MCL. Although intensive chemotherapy and allogeneic stem cell transplants were performed on the patient, he died 18 months after initial presentation.
Due to its rarity, the diagnosis of MCL without typical immunophenotype and genetic aberrations is particularly challenging. Comprehensive investigation of clinical and pathological features to exclude other T+ myeloid neoplasms is necessary.
肥大细胞白血病(MCL)是系统性肥大细胞增多症(SM)的一种非常罕见的形式,占所有肥大细胞增多症的比例不到0.5%。MCL的诊断需要满足SM标准,同时伴有非典型肥大细胞(MCs)浸润骨髓(BM)、外周血以及皮肤外器官。MCL是一种致命疾病,几乎总是表现出侵袭性,中位生存时间仅约6个月。在此,我们报告一例罕见的原发性MCL病例,该病例无CD25表达和KIT突变。
一名此前健康的13岁男孩因偶然发现右侧扁桃体肿大而转诊至我院。在其右侧扁桃体、骨髓和多个淋巴结中发现了中等大小造血母细胞的弥漫性浸润。随后发现肿瘤细胞群通过表达CD117和类胰蛋白酶表现出向肥大细胞系的分化,但该细胞群缺乏CD25/CD2表达以及KIT基因的激活突变。发现了异常核型,但未发现白血病相关融合基因。随后证实外周血、骨骼和肺部受累。最重要的鉴别诊断包括类胰蛋白酶阳性(T+)急性髓系白血病、髓肥大细胞白血病和嗜碱性粒细胞白血病。异常MCs的形态学特征和浸润模式支持MCL的最终诊断。尽管对该患者进行了强化化疗和异基因干细胞移植,但他在初次就诊后18个月死亡。
由于其罕见性,诊断无典型免疫表型和基因畸变的MCL极具挑战性。有必要全面调查临床和病理特征以排除其他T+髓系肿瘤。